Elanco fined $15m for Reg S-K misrepresentations
Elanco’s use of sales incentives created misleading impressions of customer demand, the SEC stated.
Article label: Quick Read
Premium article
Elanco, a veterinary pharmacology company, agreed to settle charges with the SEC over accusations that it made misleading statements about its revenue growth and user demand. The company will pay a $15m penalty without admitting or denying the charges.
The SEC’s charges arise from deficiencies in Elanco’s Regulation S-K
